Sfmg LLC Takes Position in Elanco Animal Health (NYSE:ELAN)

Sfmg LLC purchased a new stake in shares of Elanco Animal Health (NYSE:ELAN) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 36,520 shares of the company’s stock, valued at approximately $1,076,000.

Several other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of Elanco Animal Health by 4.7% during the second quarter. BlackRock Inc. now owns 20,483,172 shares of the company’s stock valued at $692,331,000 after purchasing an additional 924,059 shares in the last quarter. State Street Corp boosted its position in Elanco Animal Health by 46.3% during the 3rd quarter. State Street Corp now owns 9,763,351 shares of the company’s stock worth $259,608,000 after buying an additional 3,087,565 shares during the period. California Public Employees Retirement System boosted its position in Elanco Animal Health by 1.4% during the 4th quarter. California Public Employees Retirement System now owns 1,437,010 shares of the company’s stock worth $42,320,000 after buying an additional 19,571 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Elanco Animal Health by 0.6% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,393,520 shares of the company’s stock worth $41,039,000 after acquiring an additional 7,999 shares during the last quarter. Finally, Global Thematic Partners LLC bought a new stake in Elanco Animal Health during the 4th quarter worth approximately $36,821,000. 99.08% of the stock is currently owned by institutional investors.

ELAN has been the subject of several analyst reports. TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Tuesday, December 24th. Morgan Stanley upgraded shares of Elanco Animal Health from an “equal” rating to an “equal weight” rating and cut their price target for the stock from $34.00 to $32.00 in a report on Thursday, November 7th. Raymond James initiated coverage on shares of Elanco Animal Health in a research note on Thursday, January 9th. They issued a “market perform” rating on the stock. Gabelli restated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, January 14th. Finally, Bank of America raised Elanco Animal Health from a “neutral” rating to a “buy” rating and set a $34.00 target price for the company in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company’s stock. Elanco Animal Health has an average rating of “Hold” and an average price target of $33.24.

NYSE:ELAN traded up $0.10 on Monday, reaching $31.49. 2,191,757 shares of the stock traded hands, compared to its average volume of 6,999,769. The company has a current ratio of 3.12, a quick ratio of 1.67 and a debt-to-equity ratio of 0.43. Elanco Animal Health has a 1-year low of $25.25 and a 1-year high of $35.46. The company’s 50 day moving average is $30.04 and its 200-day moving average is $28.47. The firm has a market capitalization of $11.71 billion, a price-to-earnings ratio of 121.12, a price-to-earnings-growth ratio of 2.96 and a beta of 0.72.

In other news, Director John P. Bilbrey acquired 3,766 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was bought at an average cost of $26.58 per share, for a total transaction of $100,100.28. Following the completion of the transaction, the director now directly owns 2,783 shares in the company, valued at approximately $73,972.14. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.04% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Further Reading: Guidelines for Successful Channel Trading

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.